Anuh Pharma board meet on May 20, 2026: dividend

Key update from the company

Anuh Pharma Ltd has scheduled a Board of Directors meeting for May 20, 2026. The company said the agenda includes approval of audited financial results for the fourth quarter and the year ended March 31, 2026. It will also consider a dividend for the financial year ended March 31, 2026. Along with the financial agenda, the board will consider the re-appointment of two directors. The intimation also includes a compliance update on the trading window closure for designated persons.

What the board will consider on May 20, 2026

The company’s board will take up a standard year-end set of items, led by audited results. Approval of audited numbers is a key trigger for investor focus because it finalises the reported performance for the full year and often sets the base for future disclosures. The board will also consider a dividend for FY ended March 31, 2026. Dividend proposals at this stage are typically subject to shareholder approval where required under applicable processes. The agenda also includes the re-appointment of Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal.

Trading window closure: dates and scope

Anuh Pharma has stated that the trading window is closed from April 1 to May 22, 2026 for designated persons. Such closures are commonly disclosed around periods when unpublished price sensitive information, such as audited financial results, is expected to be discussed and finalised. The stated reopening date extends beyond the board meeting date, indicating the closure continues after the meeting. Investors typically track these timelines as part of governance and compliance signals, especially in the lead-up to results.

Another board meeting mentioned: quarter ended December 31, 2025

Separate from the May 2026 meeting, the provided disclosures also reference a board meeting intimation for consideration and approval of unaudited financial results for the quarter ended December 31, 2025. That meeting was scheduled on February 6, 2026. The note indicates the company informed BSE about the meeting, with the agenda to consider and approve results for that quarter. No figures for the December 2025 quarter were included in the provided text.

Corporate actions on record: bonus and dividend in 2025

The disclosures also list corporate actions from 2025. A bonus issue in the ratio of 1:1 is shown with an ex-date of July 15, 2025. A dividend of Rs 1.50 per share is shown with an ex-date of August 14, 2025. The same material includes a description that the Rs 1.50 per equity share dividend was on post-bonus share capital and represented a 30% payout on face value of Rs 5 per share, subject to shareholder approval at the AGM.

What was disclosed around FY2025 results and governance items

The provided text includes details from a board meeting held on May 23, 2025, where the company approved audited financial results for the year ending March 31, 2025. The same meeting included a 1:1 bonus equity share issue recommendation and a proposed dividend of Rs 1.50 per share, pending shareholder approval. The disclosure also notes that the statutory auditors, Jayantilal Thakkar & Co., Chartered Accountants (FRN: 104133W), submitted an unmodified opinion on the audited financial results for the financial year ended March 31, 2025.

The company also disclosed that its total assets as of March 31, 2025 were Rs 506.63 crore (converted from Rs 50,662.77 lakh stated in the source). In addition, it referenced the re-appointment of Mr. Ritesh Bipin Shah as Joint Managing Director and the re-appointment of Ankit Kishor Chande as Cost Auditor for FY 2025-26. The AGM date mentioned in the same context was August 22, 2025.

Selected financial snapshot available in the provided data

The tables in the provided text include figures for two quarters. Total income for the quarter ended June 30, 2025 was Rs 189.87 crore and net profit was Rs 8.30 crore (converted from Rs 18,986.78 lakh and Rs 830.12 lakh). For the quarter ended March 31, 2025, total income was Rs 199.54 crore and net profit was Rs 12.46 crore (converted from Rs 19,953.78 lakh and Rs 1,245.70 lakh). Earnings per share in the same table are shown as 1.66 and 2.49, respectively, for those quarters.

Dividend disclosures also include a higher payout figure

The provided material also contains a separate dividend statement: “For the year under review, the Directors have recommended Final Dividend of Rs 2.50 per share… (Rs 2.00 per share for the previous year)… The total dividend outgo shall be Rs 12.53 crore as compared to Rs 10.02 crore during the previous year.” These amounts are presented in the source as Rs 1,253 lakh and Rs 1,002 lakh, which have been converted into a single base unit (Rs crore) for consistency here.

Key facts table

Corporate actions and financial metrics table (from disclosed data)

Market impact: what investors typically track next

The May 20, 2026 board meeting is primarily a results and capital return event, based on the agenda disclosed. For investors, the audited FY2026 numbers will be the central document, because they confirm full-year performance and often include board commentary and statutory audit observations. Dividend consideration is another focal point, but the amount and structure have not been disclosed in the provided text. The trading window closure dates are relevant for governance tracking and indicate the period during which designated persons are restricted from trading.

Why this matters: governance and capital allocation signals

Board meeting intimations typically carry two signals for the market: the timing of audited reporting and whether capital allocation decisions like dividends are on the table. In this case, Anuh Pharma has clearly flagged both. The inclusion of director re-appointment items suggests the meeting also covers routine governance matters alongside financial reporting. Historical disclosures in the provided material show the company has previously coupled audited results with dividend and bonus-related decisions, such as the FY2025 board meeting outcomes.

Conclusion

Anuh Pharma’s May 20, 2026 board meeting will cover audited Q4 and FY2026 results, dividend consideration for FY ended March 31, 2026, and director re-appointments. The trading window for designated persons remains closed through May 22, 2026, as disclosed. Investors tracking the company will look for the audited results outcome and any dividend decision following the meeting.